[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"smoking--cigarette\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:smoking--cigarette":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,40,67,102,130,157,188,228,257,287],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100652149","phase-1-impact-of-sweeteners-on-the-addictive-threshold-of-nicotine-100652149",false,"NCT07771725","Impact of Sweeteners on the Addictive Threshold of Nicotine","Inclusion Criteria:\n\n* Smoking at least for one year and more frequently than once a week, smoking status confirmed with a semi-quantitative urine nicotine test. Smokers will be stratified by level of dependence, assessed with the FTND 29 low or no dependence ≤3 and moderate or high dependence ≥ 4.\n* In good health as verified by medical history, screening examination, and screening laboratory tests.\n* For women, report using acceptable birth control methods.\n\nExclusion Criteria:\n\n* History of major medical or psychiatric disorders that the physician investigator deems as contraindicated for the participant to be in the study;\n* regular current use of certain psychotropic medications (such as mood stabilizers, antipsychotics, or anxiolytics being prescribed to treat bipolar disorder, psychosis or anxiety spectrum disorders, respectively);\n* current untreated alcohol or substance use disorder for any other recreational or prescription drugs other than nicotine;\n* for women, pregnant as determined by pregnancy screening, or breastfeeding; and 5) seeking (or undergoing) treatment for tobacco dependence or smoking.","ALL","21 Years","59 Years",{"count":19,"type":20},36,"ESTIMATED","INTERVENTIONAL",[23],"PHASE1","To determine if sucralose, an artificial sweetener, modulates nicotine threshold doses for discrimination, subjective-rewarding effects, and reinforcement in smokers with varying levels of dependence.",[26],"Smoking ( Cigarette)","NOT_YET_RECRUITING","2026-08-13",{"date":30,"type":31},"2026-08-18","ACTUAL",{"date":33,"type":20},"2026-09-01",{"date":35,"type":20},"2029-12-31",{"name":37,"class":38},"Yale University","OTHER",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":47,"sex":15,"minAge":16,"maxAge":48,"enrollmentInfo":49,"targetDuration":4,"studyType":21,"phases":51,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":4},"100649748","a-study-to-assess-nicotine-uptake-from-electronic-nicotine-delivery-system-products-100649748","NCT07739797","A Study to Assess Nicotine Uptake From Electronic Nicotine Delivery System Products","An Open-Label, Randomized, 8-way Crossover Study to Assess Elements of Abuse Liability Electronic Nicotine Delivery System Products in Adult Smokers","Inclusion Criteria:\n\n1. Able to read, understand, and willing to sign an informed consent form (ICF) and complete questionnaires written in English.\n2. Generally healthy male or female, 21 to 60 years of age, inclusive, at the time of consent.\n3. Expired breath carbon monoxide level is ≥ 10 ppm and ≤ 100 ppm at Screening.\n4. Positive urine cotinine test at Screening.\n5. Smokes combustible filtered, menthol or non-menthol cigarettes, 83 mm to 100 mm in length.\n6. Agrees to smoke same UB cigarette throughout the study period. UB cigarette is defined as the cigarette brand style currently smoked most frequently by the participant.\n7. Participants must meet one (a or b) of the following tobacco use conditions:\n\n   a. Sole smoker of filtered menthol or non-menthol cigarettes who self reports: i. Smoking at least 10 cigarettes per day (on average) and inhales the smoke, for at least 6 months prior to Screening. Brief periods of abstinence due to illness, quit attempt (more than 30 days prior to Screening), or clinical study participation (more than 30 days prior to Screening) will be allowed at the discretion of an investigator b. Dual user of cigarettes and ENDS who self-reports: i. Smoking at least 10 cigarettes per day (on average) and inhales the smoke, for at least 6 months prior to Screening Visit. Brief periods of abstinence more than 30 days prior to screening due to illness, quit attempt or clinical study participation will be allowed at the discretion of an investigator, and ii. Using a nicotine-containing ENDS (cartridge or a tank system). NOTE: Cigarette smokers or ENDS users who also use other tobacco- or nicotine-containing products (e.g., smokeless tobacco, and modern oral nicotine products) on no more than one day per week will not be excluded from study participation.\n8. Response at Screening to the Fagerström Test for Nicotine Dependence (FTND) Question 1 (\"How soon after you wake up do you smoke your first cigarette?\") is either \"Within 5 minutes\" or \"6-30 minutes.\"\n9. Willing to use only UB cigarettes and ENDS IPs during the study period.\n10. Willing to abstain from tobacco and nicotine use for at least 12 hours prior to each test session.\n11. Females must be willing to use a form of contraception acceptable to an investigator from the time of signing informed consent until End-of-Study. Examples of acceptable means of birth control include, but are not limited to:\n\n    1. Surgical sterilization (hysterectomy, bilateral tubal ligation\u002Focclusion, bilateral oophorectomy, bilateral salpingectomy);\n    2. Physical barrier method (e.g., condom, diaphragm\u002Fsponge\u002Fcervical cap) with spermicide;\n    3. Non-hormone releasing intrauterine devices (IUDs) or hormone-releasing IUDs (e.g., Mirena or Kyleena);\n    4. Vasectomized partner;\n    5. Post-menopausal and not on hormone replacement therapy; or\n    6. Sexual abstinence, defined as refraining from intercourse, when this is in line with the preferred and usual lifestyle of the participant.\n12. Males must use an acceptable method of birth control from Day -1 \"check-in\" until the end of the study, unless they have had a vasectomy or are abstinent from heterosexual intercourse, or their female partner is not able to bear children.\n13. Agrees to in-clinic confinement of 10 days and 9 nights.\n\nExclusion Criteria:\n\n1. Presence of clinically significant uncontrolled cardiovascular, pulmonary, renal, hepatic, endocrine, gastrointestinal, psychiatric, hematological, neurological disease, or any other concurrent disease or medical condition that, in the opinion of an investigator, makes the study participant unsuitable to participate in this clinical study.\n2. History, presence of, or clinical laboratory test results indicating diabetes.\n3. Systolic blood pressure of \\> 160 mmHg or a diastolic blood pressure of \\> 95 mmHg, measured after being seated for five minutes at Screening and at check-in Day -1.\n4. Weight of ≤ 110 pounds (≤ 50.0 kg) at Screening.\n5. Hemoglobin level is \\\u003C 12.5 g\u002FdL for females or \\\u003C13.0 g\u002FdL for males at Screening.\n6. Scheduled treatment for asthma currently or within the past consecutive 12 months prior to the Screening Visit. As-needed treatment, such as inhalers, may be included at an investigator's discretion.\n7. Positive test for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV).\n8. Any history of cancer, except for primary cancers of skin such as localized basal cell\u002Fsquamous cell carcinoma that has been surgically and\u002For cryogenically removed.\n9. Must not be a current regular user (i.e., \\> 5 times per month) of any tobacco products other than cigarettes or ENDS within the last 6 months prior to screening.\n10. Use of any medication or substance that aids in smoking cessation, including but not limited to any NRT (e.g., nicotine gum, lozenge, patch), varenicline (Chantix®), bupropion (Wellbutrin®, Zyban®), GLP-1 agonists (e.g., Wegovy®, Mounjaro®, and Ozempic®), or lobelia extract within ≤ 30 days prior to the signing of informed consent.\n11. History or presence of bleeding or clotting disorders.\n12. Use of daily aspirin (≥ 325 mg) or other daily anticoagulants.\n13. Whole blood donation within 8 weeks (≤ 56 days) prior to the signing of informed consent and between Screening and check-in Day -1.\n\n    NOTE: Participants will be advised against scheduling a whole blood donation for at least 7 days following study completion.\n14. Plasma donation within ≤ 7 days prior to the signing of informed consent and between Screening and check-in Day -1.\n\n    NOTE: Participants will be advised against scheduling a plasma donation for at least 7 days following study completion.\n15. Participation in another clinical trial within ≤ 30 days prior to the signing of informed consent. The 30-day window for each participant will be derived from the date of the last study event in the previous study to the time of signing the ICF in the current study.\n16. Females who have a positive pregnancy test at Screening or check-in on Day -1, are pregnant, breastfeeding, or intend to become pregnant during the course of the study.\n17. Individuals ≥ 35 years of age currently using systemic, estrogen-containing contraception or hormone replacement therapy.\n18. A positive drug screen or alcohol test (urine or breath) at Screening or at check-in (Day -1), with the exception of positive results for tetrahydrocannabinol (THC). If positive for THC at check-in, a cannabis intoxication evaluation will be performed, and inclusion will be at the discretion of an investigator.\n19. Postpones a decision to quit using tobacco- or nicotine-containing products in order to participate in this study or a previous quit attempt within ≤ 30 days prior to the signing of the ICF.\n20. Has a significant history of alcoholism or drug abuse within 24 months prior to Screening, as determined by an investigator, or has a positive alcohol test at Screening or check-in on Day -1.\n21. Employed by a tobacco or nicotine company, the study site, or handles tobacco- or nicotine-containing products as part of their job.\n22. Individuals or their family members that have ongoing litigation with tobacco company(ies).\n23. Determined by an investigator to be inappropriate for this study.",true,"60 Years",{"count":50,"type":20},50,[52],"NA","This will be a randomized, open-label, 8-way crossover, single-site study designed to evaluate elements of abuse liability (AL), including subjective effects and physiological measures (pharmacodynamics \\[PD\\]), and plasma nicotine uptake (pharmacokinetics \\[PK\\]) during and following ad libitum use of electronic nicotine delivery system (ENDS) investigational products (IPs). The study will be conducted in a confinement setting among generally healthy adult smokers of combustible cigarettes and dual users of cigarettes and ENDS products.",[55,26,56],"Smoking Behaviors","Tobacco Use","2026-07-28",{"date":59,"type":31},"2026-07-31",{"date":61,"type":20},"2026-10-01",{"date":63,"type":20},"2027-04",{"name":65,"class":66},"RAI Services Company","INDUSTRY",{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":15,"minAge":75,"maxAge":76,"enrollmentInfo":77,"targetDuration":4,"studyType":21,"phases":79,"briefSummary":80,"conditions":81,"keywords":85,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":97,"leadSponsor":99,"locationsCount":101},"100647699","empowering-patients-lung-cancer-screening-uptake-empower-lcscall-100647699","NCT07711691","Empowering Patients' Lung Cancer Screening Uptake (Empower LCS\u002FCall+)","Empowering Patients' Lung Cancer Screening Uptake (Empower LCS\u002FCall+): A Multi-Site Pilot Randomized Controlled Trial","Empower LCS+","Inclusion Criteria:\n\n1. Must meet current USPSTF eligibility criteria for lung cancer screening (Current criteria: age 50-80 years old with a 20 pack-year smoking history, who currently smoke or have quit within the last 15 years)\n2. Must have an electronic health record-assigned primary care provider within University of California Irvine Health or Emory Healthcare\n3. Must have recent engagement with respective health system (i.e., office or emergency department (ED) visit, hospitalization with discharged home in the last 12 months, or a scheduled office visit in the next 3 months).\n4. Must speak English or Spanish\n5. Able and willing to provide informed consent\n\nExclusion Criteria:\n\n1. Meet the eligibility upper age limit during initial 4-month participation.\n2. Have a prior history of lung cancer.\n3. Have a new diagnosis of other cancers in the 12 months\n4. Have a chest CT or LDCT in the last 12 months\n5. Have ICD-10 code of Alzheimer's disease in EHR","50 Years","80 Years",{"count":78,"type":20},80,[52],"Lung cancer screening (LCS) with low-dose computed tomography (LDCT) can reduce the risk of dying from lung cancer, but many people who are eligible for screening do not receive it. The purpose of the Empower LCS\u002FCall+ study is to evaluate new strategies to improve lung cancer screening among adults who are eligible for screening based on current U.S. Preventive Services Task Force (USPSTF) guidelines.\n\nThis pilot randomized controlled trial will enroll approximately 80 participants from UC Irvine Health and Emory Healthcare. Participants will be randomly assigned to receive either enhanced usual care or the Empower LCS\u002FCall+ intervention. The intervention includes educational materials, reminders for patients and primary care providers, and information about financial and community resources when appropriate. Participants who do not complete lung cancer screening after the initial intervention may receive additional telephone-based navigation through the Call+ program to help identify and address barriers to screening and help with scheduling.\n\nParticipants will complete a baseline survey and follow-up surveys at 4 and 8 months, and researchers will review electronic health record information to determine whether lung cancer screening was discussed, ordered, and completed. Some participants will also be invited to complete a one-time interview about their experiences with the study.\n\nThe results of this study will help determine the feasibility, acceptability, and preliminary effectiveness of the Empower LCS\u002FCall+ intervention and will inform future efforts to improve equitable access to lung cancer screening.",[82,83,26,84],"Lung Cancer Screening","Lung Neoplasms","Early Detection of Cancer",[86,87,88,89,90,91,92],"Lung cancer screening","Low-dose computed tomography (LDCT)","Patient navigation","Natural language processing","Smoking","Health-related social needs","Multilevel intervention","2026-07-20",{"date":95,"type":31},"2026-07-22",{"date":33,"type":20},{"date":98,"type":20},"2028-12",{"name":100,"class":38},"University of California, Irvine",57,{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":106,"acronym":4,"eligibilityCriteria":107,"healthyVolunteers":47,"sex":108,"minAge":109,"maxAge":4,"enrollmentInfo":110,"targetDuration":4,"studyType":21,"phases":112,"briefSummary":113,"conditions":114,"keywords":116,"overallStatus":120,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":39},"100641755","prevention-of-postpartum-smoking-relapse-and-related-health-consequences-by-breastfeeding-promotion-100641755","NCT07661550","Prevention of Postpartum Smoking Relapse and Related Health Consequences by Breastfeeding Promotion","Inclusion Criteria:\n\n* Be pregnant\n* Be 18 years or older\n* Have quit smoking cigarettes during this pregnancy\n* Be willing to receive infant care and breastfeeding education\n* Be able to read, listen, and talk in English\n\nExclusion Criteria:\n\n* Medical conditions contraindicating breastfeeding, such as HIV infection, active tuberculosis, and breast removal\n* Current heavy drinking (≥4 standard drinks on any day or ≥8 standard drinks per week)","FEMALE","18 Years",{"count":111,"type":20},280,[52],"The objective of this randomized controlled trial is to examine the efficacy of a new intervention to prevent postpartum smoking relapse and related health consequences through breastfeeding promotion. After the pre-test, ex-smokers who are still abstinent from smoking will be randomized into either the breastfeeding intervention or the attention placebo control group. The outcomes are postpartum smoking relapse, breastfeeding practices, and maternal and child health.",[26,115],"Breastfeeding",[117,118,119],"Pregnancy","Postpartum","Relapse","RECRUITING","2026-06-16",{"date":123,"type":31},"2026-06-22",{"date":125,"type":31},"2026-01-01",{"date":127,"type":20},"2031-07-31",{"name":129,"class":38},"State University of New York at Buffalo",{"id":131,"slug":132,"hasResults":11,"nctId":133,"briefTitle":134,"officialTitle":135,"acronym":4,"eligibilityCriteria":136,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":137,"targetDuration":4,"studyType":21,"phases":139,"briefSummary":140,"conditions":141,"keywords":142,"overallStatus":120,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":39},"100619750","cigarette-filter-study-100619750","NCT07348679","Cigarette Filter Study","A Randomized Trial of Charcoal-filtered Cigarettes on Product Perceptions, Smoking Behaviors, and Toxicant Exposure","Inclusion Criteria:\n\n* Eligible subjects will be:\n\n  1. Male and female smokers who are at least 21 years of age and self-report smoking at least 5 cigarettes per day for at least the past 6 months.\n  2. Smokers of primarily non-menthol cigarettes of brands other than Natural American Spirit.\n  3. Not currently undergoing smoking cessation treatment or trying to quit.\n  4. Able to communicate fluently in English (speaking, writing, and reading).\n  5. Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the combined consent and HIPAA form.\n\nExclusion Criteria:\n\n* Subjects who self-report and\u002For present with the following criteria will not be eligible to participate in the study:\n\nSmoking Behavior\n\n1. Use of menthol or Natural American Spirit cigarettes as preferred\u002Fregular brand (defined as using \\>20% of the time).\n2. Enrollment or plans to enroll in a smoking cessation program in the next month.\n3. Provide an initial Carbon Monoxide (CO) reading \\\u003C 5 parts per million (ppm).\n\nAlcohol\u002FDrugs\n\n1. History of substance abuse (other than nicotine) in the past 12 months and\u002For currently receiving medical treatment for substance abuse.\n2. Current alcohol consumption that exceeds 25 standard drinks\u002Fweek.\n\nMedical\n\n1. Women who are pregnant, planning a pregnancy, and\u002For lactating.\n2. Any impairment including, but not limited to, visual, physical, and\u002For neurological impairments preventing the completion of procedures included within this protocol. Notable impairments will be evaluated by the PI and eligibility will be determined on a case-by-case basis.\n3. Color blindness.\n4. Serious or unstable disease within the past 12 months (e.g. heart disease, cancer). Applicable conditions will be evaluated by the Principal Investigator and eligibility will be determined on a case-by-case basis.\n\nPsychiatric\n\nAs determined by self-report:\n\n1. Lifetime history or current diagnosis of psychosis, bipolar disorder, and\u002For schizophrenia.\n2. Current diagnosis of major depression. Subjects with a history of major depression, in remission for 6 months or longer, are considered eligible.\n\nOther\n\nAdditionally, participants may be deemed ineligible for any of the following general reasons at any point throughout the study, as well as during the initial telephone screen, at the discretion of the PI:\n\n* Significant non-compliance with protocol and\u002For study design.\n* Past, current, anticipated, or pending enrollment in another research program over the study period that could potentially impact study data.\n* Any medical condition, illness, disorder, adverse event (AE), or concomitant medication that could compromise participant safety or significantly impact study performance.",{"count":138,"type":20},252,[52],"The overall purpose of this study is to determine the effects of using charcoal-filtered cigarettes on product perceptions, smoking behaviors, and biomarkers of exposure to tobacco-related toxicants. The main questions it aims to answer are:\n\nDo perceptions of cigarettes differ by their filter? Do people smoke charcoal-filtered cigarettes differently than cigarettes with conventional filters, and does this change their exposure to cigarette harms?\n\nStudy participants will complete a 5-week laboratory-based, open-label, parallel-design randomized trial. After a baseline period of smoking their preferred brand, participants will smoke charcoal-filtered or non-charcoal-filtered cigarettes for 4 weeks while completing weekly sessions to assess primary outcomes. During weekly sessions, they will smoke two cigarettes in our laboratory, provide urine and carbon monoxide samples, and complete questionnaires.",[26],[143,144,145,146,147],"smoking behavior","charcoal","cigarette filter","perceptions","biomarkers","2026-06-04",{"date":150,"type":31},"2026-06-05",{"date":152,"type":31},"2026-04-27",{"date":154,"type":20},"2030-12-31",{"name":156,"class":38},"Rutgers, The State University of New Jersey",{"id":158,"slug":159,"hasResults":11,"nctId":160,"briefTitle":161,"officialTitle":162,"acronym":4,"eligibilityCriteria":163,"healthyVolunteers":11,"sex":15,"minAge":109,"maxAge":4,"enrollmentInfo":164,"targetDuration":4,"studyType":166,"phases":4,"briefSummary":167,"conditions":168,"keywords":174,"overallStatus":120,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":186,"locationsCount":39},"100635536","measuring-communal-coping-in-dual-smoking-couples-making-a-quit-attempt-100635536","NCT07553962","Measuring Communal Coping in Dual-smoking Couples Making a Quit Attempt","Communal Coping in Dual-Smoking Couples During a Quit Attempt","Inclusion Criteria:\n\n* Are over the age of 18\n* Smoke cigarettes on a daily basis\n* Smoke at least 5 cigarettes per day on average\n* Are in a committed relationship with an individual who smokes at least 5 cigarettes per day on average and is willing to participate in the study\n* Are willing to make a smoking cessation attempt at the time of enrollment into the study (applies to only one partner).",{"count":165,"type":20},250,"OBSERVATIONAL","Smoking is the leading preventable cause of death in the United States, and quitting is especially difficult for couples who both smoke. When both partners smoke, they are less likely to quit successfully and more likely to relapse compared to people whose partner does not smoke. Research suggests that the way romantic partners interact and support each other during a quit attempt can make a real difference - but researchers do not yet know enough about what kinds of support actually help.\n\nThis study examines a concept called \"communal coping,\" which refers to when partners treat a shared health challenge - like quitting smoking - as something they are facing together as a team rather than as separate individuals. Researchers believe that couples who approach quitting this way may have better outcomes.\n\nTo study this, researchers will ask both members of dual-smoking couples to complete brief daily surveys over two weeks while making a quit attempt. These surveys will track how partners support (or discourage) each other's quitting efforts on a day-to-day basis, along with cigarette use, cravings, and stress. This will help researchers understand which relationship patterns are most helpful for quitting, and identify specific targets for future couples-based smoking cessation programs.",[169,26,170,171,172,173],"Smoking (Tobacco) Addiction","Tobacco","Tobacco Abstinence","Quitting Smoking","Smoking Cessation",[175,176,177,178],"smoking cessation","tobacco","cigarette","relationships","2026-05-13",{"date":181,"type":31},"2026-05-15",{"date":183,"type":31},"2025-03-20",{"date":185,"type":20},"2026-12-01",{"name":187,"class":38},"University of Colorado, Denver",{"id":189,"slug":190,"hasResults":11,"nctId":191,"briefTitle":192,"officialTitle":193,"acronym":194,"eligibilityCriteria":195,"healthyVolunteers":11,"sex":15,"minAge":109,"maxAge":4,"enrollmentInfo":196,"targetDuration":4,"studyType":21,"phases":198,"briefSummary":199,"conditions":200,"keywords":206,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":219,"lastUpdatePostDateStruct":220,"startDateStruct":222,"completionDateStruct":224,"leadSponsor":226,"locationsCount":4},"100638763","smoking-cessation-with-wearables-to-improve-general-oral-health-and-quality-of-life-100638763","NCT07593742","Smoking Cessation With Wearables to Improve General, Oral Health and Quality of Life","Smoking Cessation Programme in Telerehabilitation Assisted by Telemonitoring With Non-Invasive Wearable Devices for the Improvement of Oral Health, General Health and Quality of Life","Wear-Smile","Inclusion Criteria:\n\n* Subjects who smoke ≥ 5 cigarettes per day (traditional or equivalent in nicotine content in non-combustible tobacco or liquid\u002Fvape), regardless of the severity of nicotine dependence\n* Subjects ≥ 18 years of age\n* Ability and willingness to provide informed consent or presence of a legal representative who consents\n* Subjects in possession of home medical devices for measuring cardiopulmonary parameters (sphygmomanometer and pulse oximeter) (requirement applicable to participants assigned to the control group)\n\nExclusion Criteria:\n\n* Age \\\u003C 18\n* Pregnant or breastfeeding women\n* Subjects with a remote or current history of using smoking cessation methods\n* Subjects with acute dependence on alcohol or other substances of abuse other than nicotine\n* Pathologies with advanced neurocognitive degeneration\n* Unstable psychiatric conditions (subjects with active suicidal ideation, hospitalization for psychiatric reasons and\u002For changes in psychiatric medication for less than 3 months)\n* Inability or refusal to sign informed consent\n* Inability to access the integrated telemedicine platform and\u002For wearable remote monitoring devices (requirement applicable to participants assigned to the experimental group)",{"count":197,"type":20},102,[52],"Tobacco smoking remains one of the leading preventable causes of disease, disability, and premature death worldwide. According to the World Health Organization, tobacco use is responsible for more than eight million deaths each year globally, including deaths caused by direct smoking and exposure to secondhand smoke. Smoking is a major risk factor for a wide range of chronic diseases, including cardiovascular diseases, chronic respiratory diseases, several types of cancer, and numerous oral health conditions. In addition to systemic effects, tobacco use is strongly associated with oral potentially malignant disorders and oral squamous cell carcinoma, representing a significant burden for public health systems.\n\nDespite the well-documented health risks, smoking cessation remains difficult for many individuals due to the addictive properties of nicotine and the complex behavioral and psychological components associated with tobacco dependence. Multimodal smoking cessation programs that combine behavioral counseling, psychological support, and continuous monitoring have been shown to increase the likelihood of successful cessation. However, access to these programs may be limited by logistical barriers, including geographic distance, time constraints, and limited availability of specialized services.\n\nIn recent years, telemedicine and digital health technologies have emerged as promising tools to support healthcare delivery and improve access to treatment programs. Telemedicine platforms allow remote interaction between patients and healthcare professionals, facilitating communication, follow-up, and monitoring of patients over time. Additionally, wearable devices and remote monitoring systems enable the collection of physiological and behavioral data outside traditional clinical settings, providing clinicians with valuable information to support personalized interventions.\n\nThe aim of this study is to evaluate the effectiveness and feasibility of a smoking cessation program delivered through a telerehabilitation model supported by an integrated telemedicine platform and wearable remote monitoring devices. The program is designed to support individuals who smoke tobacco products, including both combustible tobacco and alternative nicotine-containing products, by providing behavioral and psychological interventions combined with continuous remote monitoring.\n\nParticipants enrolled in the study will be assigned to one of two groups. The intervention group will participate in a telerehabilitation program delivered through a dedicated telemedicine platform. This program will include structured behavioral and psychological treatment sessions aimed at supporting smoking cessation, along with remote monitoring through non-invasive wearable devices that allow healthcare professionals to track selected physiological parameters and patient engagement during the treatment process.\n\nThe control group will receive the same multimodal behavioral and psychological treatment program but delivered through conventional rehabilitation methods without the use of telemedicine technologies or wearable monitoring devices.\n\nBy comparing these two approaches, the study aims to explore whether the integration of telemedicine and wearable technologies into smoking cessation programs may improve patient engagement, facilitate monitoring, and potentially enhance the effectiveness of behavioral interventions aimed at reducing tobacco use. The findings of this study may contribute to the development of innovative digital health strategies for smoking cessation and provide evidence to support the integration of telemedicine into addiction treatment and preventive healthcare programs.",[26,169,55,173,201,202,203,204,205],"Smoking Dependence","Smoking Addiction","Smoking Cessation Intervention","Smoking E-cigarette","Smoking Abstinence",[90,207,208,170,209,210,211,212,213,214,215,216,217,218],"Smoking cessation","Smoking addiction","Wearable device","Telerehabilitation","Oral Health","Periodontal Health","General Health","Quality of life","Periodontal disease","E-cigarette","Heat not burn tobacco","Smoking abstinence","2026-05-11",{"date":221,"type":31},"2026-05-18",{"date":223,"type":20},"2026-06-01",{"date":225,"type":20},"2027-11-01",{"name":227,"class":38},"University of Salerno",{"id":229,"slug":230,"hasResults":11,"nctId":231,"briefTitle":232,"officialTitle":233,"acronym":4,"eligibilityCriteria":234,"healthyVolunteers":47,"sex":15,"minAge":109,"maxAge":48,"enrollmentInfo":235,"targetDuration":4,"studyType":166,"phases":4,"briefSummary":237,"conditions":238,"keywords":241,"overallStatus":120,"whyStopped":4,"lastUpdateSubmitDate":248,"lastUpdatePostDateStruct":249,"startDateStruct":251,"completionDateStruct":253,"leadSponsor":255,"locationsCount":39},"100638628","acute-ocular-effects-of-cigarette-smoking-100638628","NCT07580040","Acute Ocular Effects of Cigarette Smoking","Acute Effects of Cigarette Smoking on Corneal Tomographic and Biometric Parameters: A Prospective Controlled Study","Inclusion Criteria:\n\n* Healthy adults aged 18 to 60 years\n* Current smokers in the smoking group\n* Never-smokers in the control group\n* Willing and able to undergo ophthalmic examination and Pentacam AXL measurements\n\nExclusion Criteria:\n\n* History of ocular surgery or ocular trauma\n* Presence of corneal disease, retinal disease, or ocular surface disorder\n* Clinically significant dry eye disease\n* Contact lens use within the last 2 weeks\n* Use of medications that may affect the ocular surface or pupillary dynamics, including anticholinergics or sympathomimetics\n* Systemic diseases such as diabetes mellitus or hypertension\n* Former smoking history in the control group\n* Use of electronic cigarettes or other tobacco products\n* Inability to cooperate adequately for accurate measurement",{"count":236,"type":20},90,"This prospective study aims to evaluate the short-term effects of smoking on corneal tomographic and biometric measurements in healthy adults. After baseline examinations and measurements are taken in both smoking and non-smoking participants, the same measurements will be repeated after 10 minutes of external exposure, and within-group and between-group changes will be compared. The aim of the study is to determine whether acute smoking exposure leads to measurable immediate changes in corneal tomographic and biometric parameters.",[26,239,240],"Cornea","Anterior Eye Segment Measurements",[242,243,244,245,246,247],"Cigarette Smoking","Corneal Tomography","Biometry","Pentacam","Anterior Segment","Corneal Densitometry","2026-05-05",{"date":250,"type":31},"2026-05-12",{"date":252,"type":31},"2026-02-15",{"date":254,"type":20},"2026-05",{"name":256,"class":38},"Istanbul University",{"id":258,"slug":259,"hasResults":11,"nctId":260,"briefTitle":261,"officialTitle":262,"acronym":263,"eligibilityCriteria":264,"healthyVolunteers":11,"sex":15,"minAge":109,"maxAge":4,"enrollmentInfo":265,"targetDuration":4,"studyType":21,"phases":267,"briefSummary":268,"conditions":269,"keywords":271,"overallStatus":120,"whyStopped":4,"lastUpdateSubmitDate":279,"lastUpdatePostDateStruct":280,"startDateStruct":282,"completionDateStruct":283,"leadSponsor":284,"locationsCount":286},"100635016","effect-of-non-surgical-periodontal-therapy-on-salivary-biomarkers-in-smokers-and-non-smokers-with-periodontitis-100635016","NCT07547202","Effect of Non-Surgical Periodontal Therapy on Salivary Biomarkers in Smokers and Non-Smokers With Periodontitis","The Significance of Non-Surgical Periodontal Therapy on Salivary Dkk-1, Sclerostin, and PLAP-1 Levels in Smoker and Non-Smoker Patients With Periodontitis: A Clinical Comparative Study","NSPT-Biomarker","Inclusion Criteria:\n\n* Systemically healthy.\n* Diagnosed with Stage II and III periodontitis.\n* Presence of ≥ 20 teeth (excluding third molars).\n* Current smoker OR non-smoker\n\nExclusion Criteria:\n\n* Presence of systemic diseases affecting the periodontium.\n* Use of medications affecting inflammation.\n* Received periodontal therapy in the past 6 months.\n* Received antibiotic therapy in the last 3 months.\n* Alcohol use.",{"count":266,"type":20},44,[52],"This study evaluates the effect of non-surgical periodontal therapy on salivary biomarkers (Dkk-1, Sclerostin, and PLAP-1) and clinical periodontal parameters in patients with periodontitis. Periodontitis is a chronic inflammatory disease that destroys tooth-supporting tissues. Smoking is a significant risk factor that worsens periodontal destruction and reduces the effectiveness of standard therapies.\n\n* The trial is a non-randomized comparative clinical study.\n* It includes 44 adult patients diagnosed with Stage II and III periodontitis.\n* The participants are divided into two equal groups: 22 current smokers and 22 non-smokers.\n* Participants will undergo a baseline examination, followed by standardized non-surgical periodontal therapy consisting of scaling and root planing.\n* A follow-up visit will be conducted six weeks post-therapy to repeat clinical measurements and saliva collection.\n* The primary objective is to evaluate changes in salivary biomarker levels and clinical parameters (Plaque Index, Gingival Index, bleeding on probing, Probing Pocket Depth, Clinical Attachment Level) after treatment.",[270,26],"Periodontitis",[270,90,272,273,274,275,276,277,278],"Non-surgical periodontal therapy","Scaling and root planing","Salivary biomarkers","Dkk-1","Sclerostin","PLAP-1","SOST","2026-04-20",{"date":281,"type":31},"2026-04-23",{"date":125,"type":31},{"date":61,"type":20},{"name":285,"class":38},"Al-Mustansiriyah University",2,{"id":288,"slug":289,"hasResults":11,"nctId":290,"briefTitle":291,"officialTitle":292,"acronym":4,"eligibilityCriteria":293,"healthyVolunteers":11,"sex":15,"minAge":109,"maxAge":4,"enrollmentInfo":294,"targetDuration":4,"studyType":21,"phases":296,"briefSummary":297,"conditions":298,"keywords":299,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":310,"lastUpdatePostDateStruct":311,"startDateStruct":313,"completionDateStruct":315,"leadSponsor":317,"locationsCount":39},"100631781","effectiveness-of-brief-smoking-cessation-counselling-in-pre-anaesthesia-assessment-clinic-100631781","NCT07505147","Effectiveness of Brief Smoking Cessation Counselling in Pre-Anaesthesia Assessment Clinic","A Pilot Randomized Controlled Trial: Effectiveness of Brief Smoking Cessation Counselling in Pre-Anaesthesia Assessment Clinic (PAAC)","Inclusion Criteria:\n\n* Adult patients (≥18 years)\n* Current smokers attending the pre-anaesthetic assessment clinic\n* Scheduled for elective surgery within 6 months\n\nExclusion Criteria:\n\n* Emergency surgery\n* Patients having surgery day less than 7 days\n* Cognitive impairment preventing consent\n* Patients already receiving active treatment from other smoking cessation services",{"count":295,"type":20},125,[52],"The goal of this clinical trial is to evaluate whether a brief, nurse-delivered smoking cessation intervention can increase pre-operative smoking abstinence and improve perioperative outcomes among adult elective surgical patients who are current smokers. The main questions it aims to answer are:\n\nDoes a perioperative nurse-delivered AWARD brief counselling intervention with active referral and a tailored perioperative smoking cessation booklet increase the 7-day point prevalence abstinence rate on the day of surgery, biochemically validated by exhaled carbon monoxide and salivary cotinine?\n\nIs this intervention feasible and acceptable in the pre-anaesthetic assessment clinic in terms of recruitment, retention, intervention fidelity, and patient compliance?\n\nResearchers will compare patients receiving the nurse-led AWARD brief counselling plus active referral and tailored perioperative booklet to patients receiving usual pre-anaesthetic care without structured smoking cessation counselling, to see if the intervention leads to higher pre-operative abstinence and signals of reduced post-operative complications.\n\nParticipants will:\n\nAttend the pre-anaesthetic assessment clinic where eligibility and baseline data (e.g., smoking behavior, readiness to quit, sociodemographic information) are collected and exhaled carbon monoxide is measured.\n\nBe randomly assigned to either receive brief AWARD-model counselling with active referral and a tailored perioperative smoking cessation booklet from a trained perioperative nurse, or to continue with usual pre-anaesthetic care.\n\nHave their smoking status reassessed on the day of surgery (including repeat CO and salivary cotinine testing) and at 1-month follow-up, along with collection of post-operative complication data and patient satisfaction with the smoking cessation support.",[26],[300,301,302,303,304,305,306,307,308,309],"Perioperative smoking cessation","Elective surgical patients who smoke","Nurse-led brief intervention","AWARD smoking cessation model","Pre-anaesthetic assessment clinic","Randomized controlled pilot trial","Carbon monoxide breath testing","Salivary cotinine validation","Postoperative pulmonary and wound complications","Perioperative nurse smoke cessation counselling","2026-03-26",{"date":312,"type":31},"2026-04-01",{"date":314,"type":20},"2026-04",{"date":316,"type":20},"2027-03",{"name":318,"class":38},"Pok Oi Hospital"]